4743.TWO Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 01:30):

Stats
Today's Volume	6.46M
Average Volume	2.10M
Market Cap	65.99B
EPS	TWD0 ( 2024-03-05 )
Next earnings date	( TWD0 ) 2024-05-09
Last Dividend	TWD0 ( N/A )
Next Dividend	TWD0 ( N/A )
P/E	-44.09
ATR14	TWD0.339 (0.23%)

Volume Correlation

Long: -0.37 (neutral)

Short: -0.95 (very strong negative)

Signal:(35.812) Neutral

Oneness Biotech Co., Ltd. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Oneness Biotech Co., Ltd. Correlation - Currency/Commodity

0.07
( neutral )

0.23
( neutral )

0.00
( neutral )

0.01
( neutral )

-0.78
( moderate negative )

0.12
( neutral )

Oneness Biotech Co., Ltd. Financials

Annual	2023
Revenue:	TWD86.78M
Gross Profit:	TWD-381.69M (-439.82 %)
EPS:	TWD-2.91

Q4	2023
Revenue:	TWD25.67M
Gross Profit:	TWD-100.07M (-389.79 %)
EPS:	TWD-1.070

Q3	2023
Revenue:	TWD19.03M
Gross Profit:	TWD6.75M (35.48 %)
EPS:	TWD-0.500

Q2	2023
Revenue:	TWD19.89M
Gross Profit:	TWD6.40M (32.15 %)
EPS:	TWD-0.740

Financial Reports:

No articles found.

Oneness Biotech Co., Ltd.

Oneness Biotech Co., Ltd engages in the research and development of new drugs, and sale of pharmaceutical and health products in Taiwan. It operates through New Drug Research and Development, and Agricultural Products Cultivation segments. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers; and OB318, an anti-cancer drug that is in Phase I clinical trials. It is also developing FB704A that has completed Phase I clinical trial for the treatment of rheumatoid arthritis and systemic sclerosis; FB825, which is in Phase II clinical trial for treating atopic dermatitis, allergic diseases, and asthma; and FB918, a human monoclonal antibody, which is in pre-clinical stage for the treatment of allergic asthma. In addition, the company engages in the management of agriculture cultivation and trading business; and sale of agricultural products. The company was incorporated in 2008 and is headquartered in Taipei City, Taiwan.